Immuno Nano Med
PrivateLast Round
Grant
Nov 19, 2025
Total Funding Raised
$360,000
Company Overview
Immuno Nano Med is a biotechnology company developing room-temperature-stable, dry powder influenza vaccines designed to provide broad, needle-free immunity and eliminate global cold chain dependencies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Advanced Materials, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immuno Nano Med Comps
Public and private peers based on sector, stage, and business model.
Immuno Nano Med Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 19, 2025 | ||||
| Grant | Oct 1, 2025 | ||||
| Grant | Aug 22, 2025 | ||||
| Accelerator | Aug 22, 2025 |
Immuno Nano Med Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 19, 2025
$15K raised from University of Iowa John Pappajohn Entrepreneurial Center.
- Oct 1, 2025
$305K grant awarded by the National Science Foundation.
Immuno Nano Med Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immuno Nano Med's valuation, stock price, and market status.